Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Tue, Jan 28, 2025
[Archive]
Volume 37, Issue 1 (2-2023)
Med J Islam Repub Iran 2023 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nabavi M, Arshi S, Bemanian M H, Fallahpour M, Molatefi R, Rekabi M, et al . Investigation of the Relationship between Aspirin-Sensitivity and Poor Response to Medical Management in NSAIDs-exacerbated Respiratory Disease Patients with Sinonasal Polyposis. Med J Islam Repub Iran 2023; 37 (1) :522-528
URL: http://mjiri.iums.ac.ir/article-1-8054-en.html
URL: http://mjiri.iums.ac.ir/article-1-8054-en.html
Mohammad Nabavi 
, Saba Arshi , Mohammad Hasan Bemanian , Morteza Fallahpour , Rasoul Molatefi , Mahsa Rekabi , Narges Eslami , Javad Ahmadian , Kian Darabi , Gholamreza Sedighi , Zeinab Moinfar , Fatemeh Faraji , Majid Khoshmirsafa , Sima Shokri
, Saba Arshi , Mohammad Hasan Bemanian , Morteza Fallahpour , Rasoul Molatefi , Mahsa Rekabi , Narges Eslami , Javad Ahmadian , Kian Darabi , Gholamreza Sedighi , Zeinab Moinfar , Fatemeh Faraji , Majid Khoshmirsafa , Sima Shokri
Allergy and Clinical Immunology Department, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran , Shokri.s@iums.ac.ir
Abstract: (970 Views)
Background: NSAID-exacerbated respiratory disease (N-ERD) is a highly heterogeneous disorder with various clinical symptoms. The aspirin challenge test is a gold standard method for its diagnosis, and there are still no reliable in vitro diagnostic biomarkers yet. Oral challenge tests are time-consuming and may be associated with a risk of severe systemic reactions. This study aimed to evaluate whether patients with poor responses to medical management are more susceptible to being aspirin-sensitive.
Methods: In this cohort study, after CT scanning of all patients and subject selection, conventional medical treatment was started as follows and continued for three consecutive months: at first, saline nose wash twice per day, intranasal beclomethasone spray one puff in each nostril twice per day, montelukast 10 mg tablet once daily, a ten-day course of oral prednisolone starting with the dose of 25 mg per day and taper and discontinued thereafter. Sinonasal outcome test 22 (SNOT22) was used for the evaluation of symptom severity. Statistical analyses were performed with SPSS version 23, and data were analyzed using an independent samples T-test, paired T-test, and Receiver operating curve analysis
Results: 25 males and 53 females were enrolled in this study, with an average age of 41.56 ± 11.74 years old (18-36). Aspirin challenge test results were positive in 29 (37.2%) patients. The average SNOT22 scores before the treatment were 52.97 ± 17.73 and 47.04 ± 18.30 in aspirin-sensitive and aspirin-tolerant patients, respectively, and decreased to 27.41 ± 16.61 and 24.88 ± 16.72 in aspirin-sensitive and aspirin-tolerant patients after the treatment, respectively. There was no significant difference in SNOT22 scores between the groups.
Conclusion: The severity of symptoms before treatment and clinical improvement after treatment are not good predictors of N-ERD.
Methods: In this cohort study, after CT scanning of all patients and subject selection, conventional medical treatment was started as follows and continued for three consecutive months: at first, saline nose wash twice per day, intranasal beclomethasone spray one puff in each nostril twice per day, montelukast 10 mg tablet once daily, a ten-day course of oral prednisolone starting with the dose of 25 mg per day and taper and discontinued thereafter. Sinonasal outcome test 22 (SNOT22) was used for the evaluation of symptom severity. Statistical analyses were performed with SPSS version 23, and data were analyzed using an independent samples T-test, paired T-test, and Receiver operating curve analysis
Results: 25 males and 53 females were enrolled in this study, with an average age of 41.56 ± 11.74 years old (18-36). Aspirin challenge test results were positive in 29 (37.2%) patients. The average SNOT22 scores before the treatment were 52.97 ± 17.73 and 47.04 ± 18.30 in aspirin-sensitive and aspirin-tolerant patients, respectively, and decreased to 27.41 ± 16.61 and 24.88 ± 16.72 in aspirin-sensitive and aspirin-tolerant patients after the treatment, respectively. There was no significant difference in SNOT22 scores between the groups.
Conclusion: The severity of symptoms before treatment and clinical improvement after treatment are not good predictors of N-ERD.
Keywords: N-ERD, Aspirin-sensitive, Aspirin-tolerant, Chronic rhinosinusitis, Nasal polyposis, Asthma, SNOT22
Type of Study: Original Research |
Subject:
Immunology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
